Evaxion Biotech
EVAX | NASDAQ
$2.77
+$0.03 (+0.96%)
At close: Nov 16, 2026, 4:00 PM ET
$2.77
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 4:10 PM ET
+0.96%
(1D)No price chart data available for 1D timeframe.
Rating
56.2
Fundamentals Strong
Market Sentiment Neutral
Moat None
Sector Rank #165/1021 (Top 16%)
Key Statistics
Market Data
Market Cap $17.5M
1D Range
2.77 2.89
52W Range
2.74 6.63
Valuation (TTM)
PE -0.45
PB 1.84
EV/EBITDA -1.07
Valuation (NTM)
Forward PE 84.28
Forward PEG 0.00
Price Target $9.50
Cash Flow
FCF Yield 0.0%
SBC Adj. FCF Yield 0.0%
SBC Impact N/A
Margins
Gross Margin 100.0%
Operating Margin -116.0%
FCF Margin 0.0%
Growth (CAGR)
Revenue 3Y | 5Y 98.9% |
83.0%
Dil EPS 3Y | 5Y 53.2% |
44.8%
FCF 3Y | 5Y 150.0% |
70.8%
Returns
ROA -44.6%
ROE -61.4%
ROIC -46.7%
Financial Health
Net Cash
$8.34M
Current Ratio 5.06
Interest Coverage -11.89
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and vira...
Sector Healthcare
Industry Biotechnology
Employees 46
IPO Date Feb 5, 2021
Website evaxion.ai
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
2
Consensus
Buy
Price Target
$9.50
Upside
+242.96%
Buy (2)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove EVAX